Clinical Trials Logo

Biliary Cancer Metastatic clinical trials

View clinical trials related to Biliary Cancer Metastatic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05074472 Completed - Solid Tumor, Adult Clinical Trials

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Start date: January 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where prevalence of CSP expression is high. Approximately 12 to 24 patients will be enrolled in the Dose Escalation Stage; the total number of patients will depend on the dose level at which the RP2D is defined. Patients who meet the eligibility criteria during Screening will enter the treatment period. ZB131 will be given via IV every week. Patients will be treated until disease progression or unacceptable toxicities occur.

NCT ID: NCT03464968 Completed - Clinical trials for Biliary Cancer Metastatic

mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line

Start date: July 29, 2015
Phase: Phase 2
Study type: Interventional

In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin, efficacy of mFOLFOX vs. mFOLFIRI will be evaluated at randomized phase 2 trial.

NCT ID: NCT03222258 Completed - Clinical trials for Stage IV Breast Cancer

Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients

Start date: December 17, 2016
Phase:
Study type: Observational

This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study. Participants will be separated into different groups by their intentions for using palliative care. Every participant will carry out the questionnaire per 3 months. This cohort study will be ended a year after each participant enrolls. However, if the participant didn't survive during this study, the caregivers will be asked to fill out additional questionnaire after 3 months of the death.